NEW YORK, Aug. 29, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit
has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Lipocine Inc. (NASDAQ:LPCN)
securities between June 30, 2015 and June 28, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/lipocine. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, defendants issued materially false and/or misleading
statements and/or failed to disclose that: (1) Lipocine’s filing of its New Drug Application for LPCN 1021, Lipocine’s lead product
candidate, contained deficiencies; and (2) as a result, defendant’s statements about Lipocine’s business and operations were false
and misleading and/or lacked a reasonable basis.
On June 29, 2016, Lipocine announced that the U.S. Food and Drug Administration had issued a Complete Response
Letter regarding the Company’s New Drug Application for LPCN 1021. According to the Complete Response Letter, the FDA has
identified deficiencies related to the dosing algorithm for the label and concluded the application was not ready for approval in
its present form.
If you suffered a loss in Lipocine you have until August 30, 2016 to request that the Court appoint you as lead
plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional
information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/lipocine.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving
financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar
outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: vw@wongesq.com
